Three generic drugmakers reach settlements in 45-state price-fixing lawsuit
Ascend Laboratories and Mayne Pharma will pay a combined $1.05 million, and Citron Pharma agreed to non-monetary terms, Connecticut Attorney General William Tong's office said Thursday. Maine, Massachusetts, New Hampshire, Rhode Island and Vermont are among the states taking part.
A coalition of 45 states and territories led by Connecticut has asked a court to approve settlements with three generic drug manufacturers accused of conspiring to inflate prices and limit competition, Connecticut Attorney General William Tong's office said Thursday.
Under the proposed settlements, Ascend Laboratories will pay $400,000 to the states and Mayne Pharma will pay $650,000, according to the attorney general's office. Citron Pharma's settlement includes only non-monetary terms because the company has ceased business operations, the office said. Each company also agreed to internal reforms meant to ensure fair competition and compliance with antitrust laws.
The states allege that the companies took part in a widespread, long-running conspiracy to artificially raise and manipulate prices for numerous generic prescription drugs. The settlements resolve those allegations against the three companies and must still be approved by the court.
Maine, Massachusetts, New Hampshire, Rhode Island and Vermont are among the states joining the settlements.
The states previously reached settlements with Sandoz, Glenmark, Lannett, Bausch, Apotex, Heritage and Heritage's parent company, Emcure, totaling $496.5 million, Tong's office said.
Connecticut has led the multistate antitrust effort since 2016, filing a series of complaints against dozens of generic drug manufacturers and their executives. The first trial, focused on 80 topical generic drugs and naming 26 companies and 10 people, is scheduled to be held in Hartford in February 2027.
"One by one, we are holding these companies accountable," Tong said.
The attorney general's office said people who bought a generic prescription drug in the United States between May 2009 and December 2019 may be eligible for compensation and can find claim information at AGGenericDrugs.com.
This brief was drafted by AI from a public agency or political press release and published by The New England Signal. Why we use AI for stories like this one.